A Phase 1 interventional study of VH4011499 and Placebo in HIV Infections, sponsored by ViiV Healthcare. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-01.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 110th largest by enrollment of the 210 interventional ones that give a count, is one of 6 that started in 2022, is one of 83 in phase 1, and was the 228th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in Romania, South Africa, Uganda
ViiV Healthcare · Sites in Netherlands
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
By country, each count listing its studies:
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
266 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 85 · Phase 2 53 · Phase 3 68 · Phase 4 18
First in 1994; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 73 is close to the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 82 across the 210 interventional studies, 328 across the 14 observational. Of the 230 that completed or were terminated, 95 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
6 of the studies in HIV Infections by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07053384ViiV HealthcareA Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV | 2027-01-22 |
| NCT07934719ViiV HealthcareMass Balance and Absolute Bioavailability of [14C]-VH4011499 | 2027-02-18 |
| NCT06786520ViiV HealthcareA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | 2027-03-08 |
| NCT07939594ViiV HealthcareAn Evaluation of the Potential for VH4011499 Drug-drug-interactions | 2027-03-12 |
| NCT07525544ViiV HealthcareA Study to Investigate the Safety and PK of VH4770359 in Healthy Participants | 2027-05-05 |
Add all 6 to your calendar (.ics) → With an account.
Among the 266 studies in HIV Infections by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This FTIH study aims to evaluate the safety, tolerability and PK of the novel investigational Human immunodeficiency virus (HIV)-1 capsid inhibitor VH4011499 in healthy adults. The study will be conducted in 3 parts: Part 1 will investigate single ascending doses (SAD) and Part 2 will investigate multiple ascending doses (MAD). Part 3 will investigate single dose of a new formulation of VH4011499. The transition from SAD to MAD will be based on the assessment of the Safety and Dose Escalation Committee.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy participants were given a single dose of placebo on Day 1 and were followed up until Day 28.
Drug: Placebo
Healthy participants were given a single dose of 25 mg VH4011499 on Day 1 and were followed up until Day 28.
Drug: VH4011499
Healthy participants were given a single dose of 125 mg VH4011499 on Day 1 and were followed up until Day 28.
Drug: VH4011499
Healthy participants were given a single dose of 200 mg VH4011499 on Day 1 and were followed up until Day 28.
Drug: VH4011499
Healthy participants were given a single dose of 625 mg VH4011499 on Day 1 and were followed up until Day 28.
Drug: VH4011499
Healthy participants were given a single dose of 1875 mg VH4011499 on Day 1 and were followed up until Day 28.
Drug: VH4011499
Healthy participants were given a dose of placebo once daily for a 14-day period and were followed up until Day 42.
Drug: Placebo
Healthy participants were given a dose of VH4011499 200 mg PiB once daily for a 14-day period and were followed up until Day 42.
Drug: VH4011499
Healthy participants were given a dose of VH4011499 300 mg once daily and a single dose of Midazolam on Days 1, 2, and 15, and were followed up until Day 42.
Drug: VH4011499 · Drug: Midazolam
Healthy participants were given a dose of VH4011499 400 mg PiB once daily for a 14-day period and were followed up until Day 42.
Drug: VH4011499
Healthy participants were given a dose of VH4011499 200 mg tablet on Day 1 and were followed up until Day 28.
Drug: VH4011499
Part 1: Number of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention.
Time frame: Up to Day 28
Part 2: Number of Participants With AEs
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention.
Time frame: Up to Day 42
Part 3: Number of Participants With AEs
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention.
Time frame: Up to Day 28
Part 1: Number of Participants With AEs by Severity
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild symptoms causing no or minimal interference with usual social \& functional activities with intervention not indicated, 2=Moderate symptoms causing greater than minimal interference with usual social \& functional activities with intervention indicated, 3=Severe symptoms causing inability to perform usual social \& functional activities with intervention or hospitalization indicated, 4=Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability or death, 5=Death.
Time frame: Up to Day 28
Part 2: Number of Participants With AEs by Severity
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild symptoms causing no or minimal interference with usual social \& functional activities with intervention not indicated, 2=Moderate symptoms causing greater than minimal interference with usual social \& functional activities with intervention indicated, 3=Severe symptoms causing inability to perform usual social \& functional activities with intervention or hospitalization indicated, 4=Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability or death, 5=Death.
Time frame: Up to Day 42
Part 3: Number of Participants With AEs by Severity
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild symptoms causing no or minimal interference with usual social \& functional activities with intervention not indicated, 2=Moderate symptoms causing greater than minimal interference with usual social \& functional activities with intervention indicated, 3=Severe symptoms causing inability to perform usual social \& functional activities with intervention or hospitalization indicated, 4=Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability or death, 5=Death.
Time frame: Up to Day 28
Part 2: Number of Participants Discontinuing Treatment Due to AEs
Number of participants who discontinued treatment due to AEs are presented.
Time frame: Up to Day 42
Part 1: Absolute Values of Liver Panel Parameters: Direct Bilirubin, Total Bilirubin
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin.
Time frame: Up to Day 28
Part 1: Absolute Values of Liver Panel Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST)
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST.
Time frame: Up to Day 28
Part 2: Absolute Values of Liver Panel Parameters: Direct Bilirubin, Total Bilirubin
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin.
Time frame: Up to Day 42
Part 2: Absolute Values of Liver Panel Parameters: ALT, ALP and AST
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST
Time frame: Up to Day 42
Part 3: Absolute Values of Liver Panel Parameters: Direct Bilirubin, Total Bilirubin
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin.
Time frame: Up to Day 28
Part 3: Absolute Values of Liver Panel Parameters: ALT, ALP and AST
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST
Time frame: Up to Day 28
Part 1: Change From Baseline in Liver Panel Parameters: Direct Bilirubin, Total Bilirubin
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.
Time frame: From Baseline (Day 1) and up to Day 28
Part 1: Change From Baseline in Liver Panel Parameters: ALT, ALP and AST
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.
Time frame: From Baseline (Day 1) and up to Day 28
Part 2: Change From Baseline in Liver Panel Parameters: Direct Bilirubin, Total Bilirubin
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value. Standard Deviation (SD)=0.0000 is defined as following: if all participants analyzed for a specific parameter at a specific time point have the same value, then SD is equal with 0.0000.
Time frame: From Baseline (Day 1) and up to Day 42
Part 2: Change From Baseline in Liver Panel Parameters: ALT, ALP and AST
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value. SD=0.00 is defined as following: if all participants analyzed for a specific parameter at a specific time point have the same value, then SD is equal with 0.00.
Time frame: From Baseline (Day 1) and up to Day 42
Part 3: Change From Baseline in Liver Panel Parameters: Direct Bilirubin, Total Bilirubin
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.
Time frame: From Baseline (Day 1) and up to Day 28
Part 3: Change From Baseline in Liver Panel Parameters: ALT, ALP and AST
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.
Time frame: From Baseline (Day 1) and up to Day 28
Part 1: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Parameters
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of the liver panel parameters: ALT, ALP, AST, total bilirubin and direct bilirubin. The number of participants with any grade increase (from grade 1 \[mild\] to grade 4 \[potentially life-threatening\]) have been presented.
Time frame: Up to Day 28
Part 2: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Parameters
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of the liver panel parameters: ALT, ALP, AST, total bilirubin and direct bilirubin. The number of participants with any grade increase (from grade 1 \[mild\] to grade 4 \[potentially life-threatening\]) have been presented.
Time frame: Up to Day 42
Part 3: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Parameters
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of the liver panel parameters: ALT, ALP, AST, total bilirubin and direct bilirubin. The number of participants with any grade increase (from grade 1 \[mild\] to grade 4 \[potentially life-threatening\]) have been presented.
Time frame: Up to Day 28
Part 1: Area Under the Plasma Concentration Time Curve (AUC) From Time Zero to Infinity (0-inf) Following Single Dose Administration of VH4011499
Blood samples were collected as assessed by protocol, at specific time points for pharmacokinetic (PK) analysis to determine AUC(0-inf). For AUC, a linear trapezoidal method was employed for all incremental trapezoids arising from increasing concentrations and the logarithmic trapezoidal method was used for those arising from decreasing concentrations. Geometric Coefficient of Variation was expressed in percentages.
Time frame: At Day 1
Part 2: AUC Over a Dosing Interval From Time of Dosing to the Time of the Subsequent Dose (0-t) Following Repeat Dose Administration of VH4011499
Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine AUC(0-t). For AUC, a linear trapezoidal method was employed for all incremental trapezoids arising from increasing concentrations and the logarithmic trapezoidal method was used for those arising from decreasing concentrations.
Time frame: At Days 1 and 14 for Part 2 (MAD): VH4011499 200 mg PiB and Part 2 (MAD): VH4011499 400 mg PiB groups, and at Days 2 and 15 for Part 2 (MAD): VH4011499 300 mg + Midazolam PiB group
Part 1: Maximum Observed Plasma Concentration (Cmax) Following Single Dose Administration of VH4011499.
Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine Cmax.
Time frame: At Day 1
Part 1: Time to Maximum Observed Plasma Concentration (Tmax) Following Single Dose Administration of VH4011499
Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine Tmax.
Time frame: At Day 1
Part 1: Apparent Terminal Half-life (T1/2) Following Single Dose Administration of VH4011499
Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine T1/2.
Time frame: At Day 1
Part 2: Cmax Following Repeat Dose Administration of VH4011499
Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine Cmax.
Time frame: At Days 1 and 14 for Part 2 (MAD): VH4011499 200 mg PiB and Part 2 (MAD): VH4011499 400 mg PiB groups, and at Days 2 and 15 for Part 2 (MAD): VH4011499 300 mg + Midazolam PiB group
Part 2: Tmax Following Repeat Dose Administration of VH4011499
Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine Tmax.
Time frame: At Days 1 and 14 for Part 2 (MAD): VH4011499 200 mg PiB and Part 2 (MAD): VH4011499 400 mg PiB groups, and at Days 2 and 15 for Part 2 (MAD): VH4011499 300 mg + Midazolam PiB group
Part 2: T1/2 Following Repeat Dose Administration of VH4011499
Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine T1/2.
Time frame: At Day 14 for Part 2 (MAD): VH4011499 200 mg PiB and Part 2 (MAD): VH4011499 400 mg PiB groups, and at Day 15 for Part 2 (MAD): VH4011499 300 mg + Midazolam PiB group
| Milestone | Part 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB) | Part 1 (SAD): VH4011499 25 mg PiB | Part 1 (SAD): VH4011499 125 mg PiB | Part 1 (SAD): VH4011499 200 mg PiB | Part 1 (SAD): VH4011499 625 mg PiB | Part 1 (SAD): VH4011499 1875 mg PiB | Part 2 Multiple Ascending Dose (MAD): Placebo PiB | Part 2 (MAD): VH4011499 200 mg PiB | Part 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiB | Part 2 (MAD): VH4011499 400 mg PiB | Part 3 (Single Dose): VH4011499 200 mg Tablet |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 10 | 6 | 6 | 6 | 6 | 6 | 7 | 6 | 8 | 6 | 6 |
| Completed | 10 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 8 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention.
| Participants | Part 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB) | Part 1 (SAD): VH4011499 25 mg PiB | Part 1 (SAD): VH4011499 125 mg PiB | Part 1 (SAD): VH4011499 200 mg PiB | Part 1 (SAD): VH4011499 625 mg PiB | Part 1 (SAD): VH4011499 1875 mg PiB |
|---|---|---|---|---|---|---|
| Part 1: Number of Participants With Adverse Events (AEs) | 3 | 2 | 1 | 3 | 1 | 1 |
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention.
| Participants | Part 2 Multiple Ascending Dose (MAD): Placebo PiB | Part 2 (MAD): VH4011499 200 mg PiB | Part 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiB | Part 2 (MAD): VH4011499 400 mg PiB |
|---|---|---|---|---|
| Part 2: Number of Participants With AEs | 2 | 3 | 3 | 2 |
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention.
| Participants | Part 3 (Single Dose): VH4011499 200 mg Tablet |
|---|---|
| Part 3: Number of Participants With AEs | 1 |
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild symptoms causing no or minimal interference with usual social \& functional activities with intervention not indicated, 2=Moderate symptoms causing greater than minimal interference with usual social \& functional activities with intervention indicated, 3=Severe symptoms causing inability to perform usual social \& functional activities with intervention or hospitalization indicated, 4=Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability or death, 5=Death.
| Participants | Part 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB) | Part 1 (SAD): VH4011499 25 mg PiB | Part 1 (SAD): VH4011499 125 mg PiB | Part 1 (SAD): VH4011499 200 mg PiB | Part 1 (SAD): VH4011499 625 mg PiB | Part 1 (SAD): VH4011499 1875 mg PiB |
|---|---|---|---|---|---|---|
| Grade 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| Grade 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 | 1 | 0 | 0 | 1 | 0 | 0 |
| Grade 4 | 0 | 1 | 0 | 0 | 0 | 0 |
| Grade 5 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild symptoms causing no or minimal interference with usual social \& functional activities with intervention not indicated, 2=Moderate symptoms causing greater than minimal interference with usual social \& functional activities with intervention indicated, 3=Severe symptoms causing inability to perform usual social \& functional activities with intervention or hospitalization indicated, 4=Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability or death, 5=Death.
| Participants | Part 2 Multiple Ascending Dose (MAD): Placebo PiB | Part 2 (MAD): VH4011499 200 mg PiB | Part 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiB | Part 2 (MAD): VH4011499 400 mg PiB |
|---|---|---|---|---|
| Grade 1 | 2 | 3 | 3 | 2 |
| Grade 2 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade 5 | 0 | 0 | 0 | 0 |
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild symptoms causing no or minimal interference with usual social \& functional activities with intervention not indicated, 2=Moderate symptoms causing greater than minimal interference with usual social \& functional activities with intervention indicated, 3=Severe symptoms causing inability to perform usual social \& functional activities with intervention or hospitalization indicated, 4=Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability or death, 5=Death.
| Participants | Part 3 (Single Dose): VH4011499 200 mg Tablet |
|---|---|
| Grade 1 | 1 |
| Grade 2 | 0 |
| Grade 3 | 0 |
| Grade 4 | 0 |
| Grade 5 | 0 |
Number of participants who discontinued treatment due to AEs are presented.
| Participants | Part 2 Multiple Ascending Dose (MAD): Placebo PiB | Part 2 (MAD): VH4011499 200 mg PiB | Part 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiB | Part 2 (MAD): VH4011499 400 mg PiB |
|---|---|---|---|---|
| Part 2: Number of Participants Discontinuing Treatment Due to AEs | 0 | 0 | 0 | 0 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin.
| Micromoles per Liter (μmol/L) | Part 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB) | Part 1 (SAD): VH4011499 25 mg PiB | Part 1 (SAD): VH4011499 125 mg PiB | Part 1 (SAD): VH4011499 200 mg PiB | Part 1 (SAD): VH4011499 625 mg PiB | Part 1 (SAD): VH4011499 1875 mg PiB |
|---|---|---|---|---|---|---|
| Direct Bilirubin, Baseline (Day 1) | 2.0520 ± 0.72100 | 2.8500 ± 1.39621 | 2.2800 ± 0.88304 | 1.9950 ± 0.69810 | 2.5650 ± 0.93661 | 3.1350 ± 1.28724 |
| Direct Bilirubin, Day 2 | 1.9152 ± 0.88964 | 2.7075 ± 0.52335 | 1.9950 ± 0.59891 | 1.9665 ± 0.49265 | 2.4510 ± 0.57905 | 3.2205 ± 1.41183 |
| Direct Bilirubin, Day 3 | 1.9665 ± 0.99465 | 2.5650 ± 0.64890 | 1.8525 ± 0.45134 | 1.7385 ± 0.56628 | 2.3940 ± 0.66668 | 3.1350 ± 1.34501 |
| Direct Bilirubin, Day 4 | 1.6416 ± 0.86895 | 2.7075 ± 0.78300 | 1.9095 ± 0.48867 | 1.6245 ± 0.81472 | 2.1375 ± 0.65562 | 2.7075 ± 1.01693 |
| Direct Bilirubin, Day 5 | 2.0007 ± 0.75641 | 2.7930 ± 0.84237 | 2.3085 ± 0.51584 | 1.7670 ± 0.35322 | 2.3940 ± 0.70919 | 3.2205 ± 1.33519 |
| Direct Bilirubin, Day 6 | 1.8639 ± 0.76239 | 2.8785 ± 0.95770 | 2.5365 ± 0.69601 | 1.9380 ± 0.51490 | 2.2515 ± 0.63447 | 3.0210 ± 1.28724 |
| Direct Bilirubin, Day 7 | 2.1375 ± 0.84256 | 2.9640 ± 0.76982 | 2.8044 ± 0.39367 | 1.6815 ± 0.67899 | 2.5650 ± 0.74144 | 3.3630 ± 1.19292 |
| Direct Bilirubin, Day 14 | 1.8620 ± 0.99872 | 2.3256 ± 1.03027 | 1.9095 ± 0.64362 | 1.4022 ± 0.44262 | 1.9494 ± 0.25933 | 2.0805 ± 0.93296 |
| Direct Bilirubin, Day 21 | 1.7955 ± 0.95123 | 2.3256 ± 0.75123 | 2.1660 ± 0.50341 | 1.4820 ± 0.27924 | 1.7385 ± 0.27396 | 2.2230 ± 1.08150 |
| Direct Bilirubin, Day 28 | 1.7613 ± 0.75641 | 2.1945 ± 0.46412 | 1.8810 ± 0.43260 | 1.7670 ± 0.45457 | 1.8525 ± 0.77549 | 2.6220 ± 1.56226 |
| Total Bilirubin, Baseline (Day 1) | 9.4050 ± 3.14793 | 12.8250 ± 5.59356 | 10.5450 ± 4.76555 | 11.6850 ± 2.27286 | 11.9700 ± 2.64912 | 13.6800 ± 6.11788 |
| Total Bilirubin, Day 2 | 10.7901 ± 3.16075 | 11.9415 ± 2.89069 | 14.0790 ± 5.31220 | 10.8015 ± 2.30290 | 13.5945 ± 3.91997 | 18.5250 ± 9.28747 |
| Total Bilirubin, Day 3 | 10.4310 ± 2.89748 | 11.9985 ± 3.02320 | 15.1620 ± 7.84192 | 11.3145 ± 2.78980 | 12.5115 ± 3.76109 | 17.1000 ± 7.15263 |
| Total Bilirubin, Day 4 | 9.6444 ± 3.82385 | 11.2290 ± 2.62398 | 12.6825 ± 6.84634 | 10.1460 ± 4.36860 | 10.9155 ± 3.62974 | 15.6465 ± 7.08175 |
| Total Bilirubin, Day 5 | 11.0637 ± 3.50450 | 12.4260 ± 2.91938 | 14.6490 ± 4.95448 | 9.9180 ± 2.30692 | 12.4545 ± 3.75331 | 17.7270 ± 7.77602 |
| Total Bilirubin, Day 6 | 10.1574 ± 3.09505 | 12.3690 ± 2.20495 | 14.5350 ± 4.44205 | 10.9725 ± 2.79189 | 12.1980 ± 4.57011 | 16.0455 ± 6.69431 |
| Total Bilirubin, Day 7 | 11.3373 ± 3.34901 | 13.1670 ± 3.67391 | 16.1766 ± 4.75214 | 9.5475 ± 4.17523 | 12.4545 ± 4.05153 | 18.1260 ± 6.43469 |
| Total Bilirubin, Day 14 | 9.1390 ± 4.16071 | 9.4050 ± 4.37138 | 9.9750 ± 3.82011 | 7.5582 ± 2.48215 | 8.2422 ± 1.28762 | 10.2885 ± 4.38563 |
| Total Bilirubin, Day 21 | 9.3195 ± 4.07958 | 9.7128 ± 2.89793 | 11.0580 ± 2.83606 | 8.2365 ± 2.10661 | 8.0370 ± 1.67894 | 10.5735 ± 4.85401 |
| Total Bilirubin, Day 28 | 9.5247 ± 3.74733 | 10.4595 ± 2.49312 | 9.0345 ± 1.56132 | 9.7185 ± 2.67858 | 9.1770 ± 2.78613 | 13.4805 ± 9.10929 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST.
| International Units per Liter (IU/L) | Part 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB) | Part 1 (SAD): VH4011499 25 mg PiB | Part 1 (SAD): VH4011499 125 mg PiB | Part 1 (SAD): VH4011499 200 mg PiB | Part 1 (SAD): VH4011499 625 mg PiB | Part 1 (SAD): VH4011499 1875 mg PiB |
|---|---|---|---|---|---|---|
| ALP, Baseline (Day 1) | 56.4 ± 20.82 | 57.2 ± 18.96 | 53.7 ± 6.50 | 63.0 ± 5.14 | 72.0 ± 29.39 | 55.0 ± 8.07 |
| ALP, Day 2 | 52.3 ± 17.23 | 56.3 ± 20.54 | 51.2 ± 5.34 | 59.3 ± 5.99 | 67.8 ± 22.63 | 48.8 ± 7.05 |
| ALP, Day 3 | 53.1 ± 16.11 | 54.8 ± 19.36 | 50.7 ± 6.86 | 58.2 ± 6.91 | 66.3 ± 21.08 | 51.7 ± 8.12 |
| ALP, Day 4 | 54.5 ± 15.63 | 55.5 ± 19.27 | 52.5 ± 6.53 | 65.0 ± 9.82 | 69.5 ± 24.60 | 52.7 ± 8.21 |
| ALP, Day 5 | 53.9 ± 14.89 | 54.0 ± 17.55 | 52.2 ± 7.22 | 62.2 ± 9.41 | 68.0 ± 21.56 | 53.0 ± 9.34 |
| ALP, Day 6 | 54.2 ± 15.85 | 53.3 ± 17.45 | 52.3 ± 8.36 | 65.0 ± 9.90 | 67.5 ± 18.72 | 52.7 ± 9.14 |
| ALP, Day 7 | 54.6 ± 15.88 | 54.2 ± 17.52 | 49.4 ± 4.56 | 65.0 ± 10.64 | 66.7 ± 22.71 | 54.0 ± 10.00 |
| ALP, Day 14 | 52.8 ± 16.59 | 59.6 ± 24.99 | 53.2 ± 7.14 | 63.6 ± 9.71 | 77.2 ± 22.62 | 53.2 ± 7.83 |
| ALP, Day 21 | 58.5 ± 22.15 | 58.8 ± 21.48 | 52.8 ± 6.24 | 66.8 ± 11.72 | 70.2 ± 20.49 | 51.3 ± 6.71 |
| ALP, Day 28 | 56.1 ± 17.62 | 59.0 ± 19.38 | 55.7 ± 7.61 | 68.5 ± 12.14 | 68.7 ± 20.75 | 51.5 ± 7.77 |
| ALT, Baseline (Day 1) | 13.9 ± 4.38 | 28.5 ± 16.01 | 24.7 ± 9.03 | 16.0 ± 4.34 | 23.8 ± 13.11 | 21.7 ± 3.44 |
| ALT, Day 2 | 14.2 ± 4.96 | 34.0 ± 24.66 | 23.2 ± 8.98 | 16.0 ± 4.98 | 19.5 ± 10.56 | 21.8 ± 8.93 |
| ALT, Day 3 | 15.7 ± 5.56 | 33.7 ± 25.95 | 22.3 ± 8.04 | 16.5 ± 5.92 | 17.5 ± 8.80 | 20.5 ± 8.48 |
| ALT, Day 4 | 16.0 ± 6.36 | 30.0 ± 19.93 | 23.2 ± 7.31 | 15.8 ± 5.78 | 18.0 ± 8.72 | 20.3 ± 7.28 |
| ALT, Day 5 | 16.1 ± 5.36 | 27.2 ± 16.82 | 22.2 ± 6.79 | 16.2 ± 6.11 | 18.2 ± 9.33 | 19.2 ± 4.96 |
| ALT, Day 6 | 17.4 ± 6.45 | 24.7 ± 14.35 | 22.0 ± 5.44 | 17.2 ± 6.49 | 17.8 ± 8.33 | 19.2 ± 4.49 |
| ALT, Day 7 | 18.7 ± 7.56 | 23.5 ± 12.63 | 23.6 ± 5.46 | 17.3 ± 6.53 | 18.2 ± 9.15 | 20.0 ± 5.59 |
| ALT, Day 14 | 19.7 ± 6.40 | 21.2 ± 9.50 | 21.5 ± 6.09 | 16.4 ± 3.44 | 21.6 ± 9.24 | 19.7 ± 3.72 |
| ALT, Day 21 | 20.5 ± 11.40 | 26.0 ± 20.25 | 24.8 ± 10.55 | 18.2 ± 3.92 | 19.5 ± 9.71 | 18.7 ± 3.61 |
| ALT, Day 28 | 24.9 ± 17.39 | 28.2 ± 24.81 | 23.8 ± 6.62 | 16.8 ± 5.42 | 18.5 ± 7.48 | 18.2 ± 3.54 |
| AST, Baseline (Day 1) | 15.0 ± 3.53 | 20.7 ± 9.65 | 20.3 ± 3.27 | 16.2 ± 2.64 | 20.0 ± 8.07 | 21.7 ± 4.27 |
| AST, Day 2 | 14.2 ± 3.43 | 23.0 ± 13.55 | 19.2 ± 3.66 | 14.3 ± 3.01 | 15.0 ± 3.29 | 18.3 ± 5.57 |
| AST, Day 3 | 15.3 ± 3.16 | 21.0 ± 9.86 | 18.2 ± 3.49 | 14.0 ± 2.37 | 14.7 ± 2.16 | 17.8 ± 4.45 |
| AST, Day 4 | 15.1 ± 3.31 | 17.5 ± 6.83 | 19.3 ± 3.61 | 14.0 ± 2.28 | 14.8 ± 2.64 | 17.8 ± 3.54 |
| AST, Day 5 | 15.2 ± 2.53 | 15.5 ± 4.51 | 18.5 ± 3.02 | 14.2 ± 2.04 | 14.8 ± 2.40 | 17.0 ± 2.76 |
| AST, Day 6 | 15.1 ± 3.41 | 14.8 ± 3.97 | 18.3 ± 3.56 | 14.3 ± 2.07 | 15.0 ± 1.79 | 17.2 ± 3.31 |
| AST, Day 7 | 16.0 ± 3.62 | 17.0 ± 5.14 | 19.0 ± 2.55 | 14.7 ± 2.42 | 14.8 ± 2.48 | 19.2 ± 5.19 |
| AST, Day 14 | 18.0 ± 5.61 | 17.4 ± 6.66 | 20.7 ± 5.65 | 17.4 ± 2.30 | 17.6 ± 3.21 | 19.5 ± 4.76 |
| AST, Day 21 | 18.6 ± 10.07 | 18.4 ± 6.15 | 20.8 ± 2.56 | 17.5 ± 2.07 | 15.8 ± 3.06 | 19.0 ± 3.46 |
| AST, Day 28 | 20.3 ± 10.19 | 32.0 ± 26.50 | 22.8 ± 5.85 | 15.7 ± 2.42 | 15.8 ± 2.71 | 19.8 ± 4.49 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin.
| μmol/L | Part 2 Multiple Ascending Dose (MAD): Placebo PiB | Part 2 (MAD): VH4011499 200 mg PiB | Part 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiB | Part 2 (MAD): VH4011499 400 mg PiB |
|---|---|---|---|---|
| Direct Bilirubin, Baseline (Day 1) | 1.6856 ± 0.34805 | 1.7670 ± 0.88304 | 1.6031 ± 0.74782 | 2.5365 ± 1.12089 |
| Direct Bilirubin, Day 2 | 1.8126 ± 0.35459 | 1.9665 ± 0.66448 | — | 2.8785 ± 1.15177 |
| Direct Bilirubin, Day 3 | 1.8810 ± 0.24183 | — | 2.1161 ± 0.56298 | — |
| Direct Bilirubin, Day 5 | 1.9238 ± 0.64551 | 2.3370 ± 0.71466 | — | 2.4510 ± 0.75447 |
| Direct Bilirubin, Day 6 | 1.8810 ± 0.24183 | — | 2.4795 ± 0.60630 | — |
| Direct Bilirubin, Day 7 | 2.1375 ± 0.40706 | 2.0805 ± 0.81949 | — | 3.2490 ± 1.23310 |
| Direct Bilirubin, Day 8 | 1.6245 ± 0.36275 | — | 2.2444 ± 0.43296 | — |
| Direct Bilirubin, Day 11 | 2.1803 ± 0.56499 | 2.1660 ± 0.62752 | — | 3.1065 ± 1.18678 |
| Direct Bilirubin, Day 12 | 1.3680 ± 0.24183 | — | 2.2871 ± 0.48312 | — |
| Direct Bilirubin, Day 14 | 2.1375 ± 0.45242 | 2.1660 ± 0.61813 | — | 3.0495 ± 1.15683 |
| Direct Bilirubin, Day 15 | 1.9665 ± 0.12092 | — | 2.2444 ± 0.37058 | — |
| Direct Bilirubin, Day 21 | 1.9665 ± 0.35596 | 1.9950 ± 0.61813 | — | 2.8785 ± 1.17190 |
| Direct Bilirubin, Day 22 | 1.7955 ± 0.36275 | — | 2.0734 ± 0.58838 | — |
| Direct Bilirubin, Day 28 | 1.5048 ± 0.38994 | 1.3965 ± 0.58657 | 1.2825 ± 0.44778 | 1.8525 ± 0.76026 |
| Direct Bilirubin, Day 35 | 1.4250 ± 0.33625 | 1.4535 ± 0.49265 | 1.3253 ± 0.27037 | 2.8500 ± 1.72927 |
| Direct Bilirubin, Day 42 | 1.5105 ± 0.36542 | 1.1115 ± 0.50438 | 1.7100 ± 0.34200 | 2.5650 ± 1.97947 |
| Total Bilirubin, Baseline (Day 1) | 10.5776 ± 2.98545 | 10.0890 ± 5.90780 | 9.5760 ± 4.36923 | 12.8250 ± 6.63163 |
| Total Bilirubin, Day 2 | 12.1752 ± 1.75806 | 13.6800 ± 6.64924 | — | 16.8720 ± 7.08416 |
| Total Bilirubin, Day 3 | 12.1410 ± 1.69281 | — | 12.5044 ± 4.14193 | — |
| Total Bilirubin, Day 5 | 12.0128 ± 2.81458 | 13.7370 ± 5.74282 | — | 15.7320 ± 4.92171 |
| Total Bilirubin, Day 6 | 10.0890 ± 1.93464 | — | 12.7181 ± 3.00651 | — |
| Total Bilirubin, Day 7 | 12.8250 ± 2.43837 | 13.2240 ± 6.58176 | — | 16.4445 ± 6.72047 |
| Total Bilirubin, Day 8 | 9.9180 ± 1.69281 | — | 13.1456 ± 2.44141 | — |
| Total Bilirubin, Day 11 | 12.7395 ± 2.48392 | 13.8510 ± 5.61547 | — | 16.4445 ± 6.63464 |
| Total Bilirubin, Day 12 | 10.6875 ± 0.36275 | — | 13.8724 ± 4.15402 | — |
| Total Bilirubin, Day 14 | 11.7563 ± 2.12378 | 13.4235 ± 4.72994 | — | 15.6465 ± 6.66132 |
| Total Bilirubin, Day 15 | 11.7990 ± 2.66014 | — | 13.9793 ± 3.89270 | — |
| Total Bilirubin, Day 21 | 12.5258 ± 0.21517 | 11.9700 ± 4.29070 | — | 16.9575 ± 7.40445 |
| Total Bilirubin, Day 22 | 11.2005 ± 2.29739 | — | 12.2479 ± 3.78959 | — |
| Total Bilirubin, Day 28 | 8.5842 ± 2.34276 | 8.1225 ± 4.03031 | 6.6904 ± 2.71983 | 8.3220 ± 3.44499 |
| Total Bilirubin, Day 35 | 9.1770 ± 2.04534 | 8.2365 ± 2.28761 | 7.5454 ± 2.29136 | 15.0195 ± 10.22140 |
| Total Bilirubin, Day 42 | 9.7755 ± 3.14643 | 7.4385 ± 2.67712 | 8.6141 ± 2.36934 | 13.0530 ± 11.74742 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST
| IU/L | Part 2 Multiple Ascending Dose (MAD): Placebo PiB | Part 2 (MAD): VH4011499 200 mg PiB | Part 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiB | Part 2 (MAD): VH4011499 400 mg PiB |
|---|---|---|---|---|
| ALP, Baseline (Day 1) | 56.0 ± 16.78 | 59.5 ± 19.69 | 69.0 ± 22.43 | 53.8 ± 10.55 |
| ALP, Day 2 | 53.8 ± 12.15 | 58.3 ± 20.97 | — | 53.2 ± 10.91 |
| ALP, Day 3 | 47.0 ± 18.38 | — | 68.6 ± 22.56 | — |
| ALP, Day 5 | 52.5 ± 10.34 | 62.2 ± 23.59 | — | 54.3 ± 11.04 |
| ALP, Day 6 | 47.0 ± 18.38 | — | 69.3 ± 21.99 | — |
| ALP, Day 7 | 50.3 ± 12.04 | 59.3 ± 20.65 | — | 54.2 ± 10.46 |
| ALP, Day 8 | 47.0 ± 18.38 | — | 71.9 ± 24.31 | — |
| ALP, Day 11 | 50.3 ± 12.92 | 54.0 ± 18.07 | — | 51.2 ± 9.77 |
| ALP, Day 12 | 47.0 ± 18.38 | — | 64.0 ± 19.95 | — |
| ALP, Day 14 | 51.8 ± 12.76 | 61.0 ± 19.78 | — | 49.7 ± 9.20 |
| ALP, Day 15 | 50.5 ± 23.33 | — | 66.5 ± 22.60 | — |
| ALP, Day 21 | 49.5 ± 12.40 | 51.8 ± 14.30 | — | 50.8 ± 10.53 |
| ALP, Day 22 | 47.0 ± 18.38 | — | 63.8 ± 18.72 | — |
| ALP, Day 28 | 53.4 ± 11.67 | 60.0 ± 14.85 | 62.6 ± 19.26 | 51.3 ± 10.67 |
| ALP, Day 35 | 47.7 ± 12.71 | 63.0 ± 34.89 | 65.5 ± 17.88 | 49.0 ± 11.37 |
| ALP, Day 42 | 52.2 ± 12.64 | 60.3 ± 18.60 | 66.5 ± 22.53 | 53.5 ± 10.65 |
| ALT, Baseline (Day 1) | 23.6 ± 8.30 | 15.8 ± 4.62 | 19.5 ± 5.71 | 19.8 ± 6.24 |
| ALT, Day 2 | 19.8 ± 6.30 | 16.0 ± 4.90 | — | 19.0 ± 6.03 |
| ALT, Day 3 | 23.5 ± 12.02 | — | 16.6 ± 4.47 | — |
| ALT, Day 5 | 17.0 ± 5.35 | 16.0 ± 4.65 | — | 17.3 ± 6.31 |
| ALT, Day 6 | 19.5 ± 9.19 | — | 15.6 ± 5.48 | — |
| ALT, Day 7 | 16.0 ± 4.24 | 14.5 ± 3.62 | — | 18.8 ± 7.47 |
| ALT, Day 8 | 20.5 ± 7.78 | — | 18.1 ± 7.86 | — |
| ALT, Day 11 | 15.3 ± 3.77 | 12.5 ± 3.73 | — | 19.5 ± 8.76 |
| ALT, Day 12 | 18.0 ± 8.49 | — | 14.8 ± 5.85 | — |
| ALT, Day 14 | 16.8 ± 4.19 | 12.2 ± 3.19 | — | 18.7 ± 7.31 |
| ALT, Day 15 | 26.0 ± 16.97 | — | 18.1 ± 7.75 | — |
| ALT, Day 21 | 16.0 ± 5.35 | 12.3 ± 3.33 | — | 18.3 ± 8.19 |
| ALT, Day 22 | 19.5 ± 10.61 | — | 17.0 ± 8.72 | — |
| ALT, Day 28 | 20.6 ± 9.29 | 16.7 ± 6.02 | 20.9 ± 7.59 | 22.3 ± 11.41 |
| ALT, Day 35 | 22.0 ± 11.76 | 28.0 ± 27.79 | 18.4 ± 5.93 | 18.3 ± 4.13 |
| ALT, Day 42 | 24.2 ± 10.38 | 14.8 ± 3.66 | 20.5 ± 5.93 | 21.8 ± 4.45 |
| AST, Baseline (Day 1) | 23.3 ± 7.45 | 17.3 ± 3.44 | 18.9 ± 2.70 | 17.7 ± 3.27 |
| AST, Day 2 | 19.6 ± 2.61 | 16.5 ± 3.02 | — | 15.3 ± 3.08 |
| AST, Day 3 | 19.0 ± 8.49 | — | 17.0 ± 2.98 | — |
| AST, Day 5 | 18.0 ± 2.83 | 16.8 ± 2.04 | — | 14.0 ± 2.10 |
| AST, Day 6 | 16.0 ± 7.07 | — | 16.0 ± 3.07 | — |
| AST, Day 7 | 17.3 ± 1.71 | 16.3 ± 2.25 | — | 14.7 ± 1.63 |
| AST, Day 8 | 17.0 ± 5.66 | — | 18.0 ± 4.69 | — |
| AST, Day 11 | 15.5 ± 2.38 | 15.8 ± 3.54 | — | 13.3 ± 2.50 |
| AST, Day 12 | 16.5 ± 4.95 | — | 15.9 ± 2.70 | — |
| AST, Day 14 | 17.3 ± 3.10 | 16.7 ± 3.50 | — | 13.8 ± 2.14 |
| AST, Day 15 | 20.0 ± 9.90 | — | 17.6 ± 4.17 | — |
| AST, Day 21 | 16.5 ± 2.08 | 15.7 ± 2.73 | — | 15.0 ± 3.16 |
| AST, Day 22 | 18.0 ± 4.24 | — | 16.6 ± 3.16 | — |
| AST, Day 28 | 20.2 ± 4.27 | 17.5 ± 3.73 | 22.6 ± 8.19 | 20.7 ± 7.84 |
| AST, Day 35 | 20.0 ± 6.63 | 26.3 ± 19.34 | 20.5 ± 3.55 | 20.2 ± 7.91 |
| AST, Day 42 | 21.7 ± 4.93 | 16.3 ± 1.75 | 19.8 ± 4.20 | 20.7 ± 3.27 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin.
| IU/L | Part 3 (Single Dose): VH4011499 200 mg Tablet |
|---|---|
| Direct Bilirubin, Baseline (Day 1) | 1.4250 ± 0.69810 |
| Direct Bilirubin, Day 2 | 2.1375 ± 0.97784 |
| Direct Bilirubin, Day 3 | 2.2515 ± 1.05642 |
| Direct Bilirubin, Day 4 | 1.9665 ± 0.94747 |
| Direct Bilirubin, Day 5 | 1.7784 ± 0.44591 |
| Direct Bilirubin, Day 6 | 2.3085 ± 1.11216 |
| Direct Bilirubin, Day 7 | 1.9950 ± 0.89619 |
| Direct Bilirubin, Day 14 | 1.9665 ± 0.69038 |
| Direct Bilirubin, Day 21 | 1.8525 ± 0.69601 |
| Direct Bilirubin, Day 28 | 2.6790 ± 2.39074 |
| Total Bilirubin, Baseline (Day 1) | 7.6950 ± 3.19912 |
| Total Bilirubin, Day 2 | 14.2500 ± 7.57873 |
| Total Bilirubin, Day 3 | 13.8225 ± 7.43283 |
| Total Bilirubin, Day 4 | 12.2550 ± 6.56575 |
| Total Bilirubin, Day 5 | 10.8756 ± 2.84755 |
| Total Bilirubin, Day 6 | 14.5920 ± 8.80586 |
| Total Bilirubin, Day 7 | 11.2290 ± 5.55123 |
| Total Bilirubin, Day 14 | 11.7705 ± 6.12879 |
| Total Bilirubin, Day 21 | 8.2365 ± 3.08827 |
| Total Bilirubin, Day 28 | 14.4495 ± 15.05412 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST
| μmol/L | Part 3 (Single Dose): VH4011499 200 mg Tablet |
|---|---|
| ALP, Baseline (Day 1) | 52.0 ± 8.12 |
| ALP, Day 2 | 50.7 ± 7.99 |
| ALP, Day 3 | 51.0 ± 8.20 |
| ALP, Day 4 | 54.3 ± 7.39 |
| ALP, Day 5 | 56.6 ± 7.73 |
| ALP, Day 6 | 54.2 ± 6.62 |
| ALP, Day 7 | 54.7 ± 6.12 |
| ALP, Day 14 | 54.7 ± 10.39 |
| ALP, Day 21 | 52.7 ± 7.61 |
| ALP, Day 28 | 56.3 ± 8.52 |
| ALT, Baseline (Day 1) | 12.7 ± 4.03 |
| ALT, Day 2 | 15.2 ± 6.74 |
| ALT, Day 3 | 15.0 ± 6.60 |
| ALT, Day 4 | 15.0 ± 8.32 |
| ALT, Day 5 | 13.0 ± 4.42 |
| ALT, Day 6 | 15.2 ± 6.85 |
| ALT, Day 7 | 15.0 ± 5.87 |
| ALT, Day 14 | 17.5 ± 8.96 |
| ALT, Day 21 | 19.2 ± 10.26 |
| ALT, Day 28 | 15.0 ± 4.38 |
| AST, Baseline | 16.7 ± 1.63 |
| AST, Day 2 | 17.3 ± 3.20 |
| AST, Day 3 | 16.3 ± 2.34 |
| AST, Day 4 | 16.5 ± 2.26 |
| AST, Day 5 | 16.6 ± 1.14 |
| AST, Day 6 | 17.2 ± 1.83 |
| AST, Day 7 | 16.3 ± 1.63 |
| AST, Day 14 | 19.3 ± 3.44 |
| AST, Day 21 | 21.0 ± 9.03 |
| AST, Day 28 | 18.5 ± 3.27 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.
| IU/L | Part 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB) | Part 1 (SAD): VH4011499 25 mg PiB | Part 1 (SAD): VH4011499 125 mg PiB | Part 1 (SAD): VH4011499 200 mg PiB | Part 1 (SAD): VH4011499 625 mg PiB | Part 1 (SAD): VH4011499 1875 mg PiB |
|---|---|---|---|---|---|---|
| Direct Bilirubin, Baseline (Day 1) | 2.0520 ± 0.72100 | 2.8500 ± 1.39621 | 2.2800 ± 0.88304 | 1.9950 ± 0.69810 | 2.5650 ± 0.93661 | 3.1350 ± 1.28724 |
| Direct Bilirubin, Day 2 | -0.1368 ± 0.54553 | -0.1425 ± 1.54248 | -0.2850 ± 0.84237 | -0.0285 ± 0.45134 | -0.1140 ± 0.62752 | 0.0855 ± 0.79289 |
| Direct Bilirubin, Day 3 | -0.0855 ± 0.99465 | -0.2850 ± 1.53963 | -0.4275 ± 0.90968 | -0.2565 ± 0.35459 | -0.1710 ± 0.78734 | 0.0000 ± 1.14965 |
| Direct Bilirubin, Day 4 | -0.4104 ± 0.49822 | -0.1425 ± 1.53868 | -0.3705 ± 0.90754 | -0.3705 ± 0.62518 | -0.4275 ± 0.55936 | -0.4275 ± 0.84985 |
| Direct Bilirubin, Day 5 | -0.0513 ± 0.58157 | -0.0570 ± 1.84384 | 0.0285 ± 1.02267 | -0.2280 ± 0.73085 | -0.1710 ± 0.66668 | 0.0855 ± 1.00148 |
| Direct Bilirubin, Day 6 | -0.1881 ± 0.49331 | 0.0285 ± 2.01872 | 0.2565 ± 1.30117 | -0.0570 ± 0.56886 | -0.3135 ± 0.63447 | -0.1140 ± 1.30976 |
| Direct Bilirubin, Day 7 | 0.0855 ± 0.56571 | 0.1140 ± 1.77928 | 0.4104 ± 1.00148 | -0.3135 ± 0.47656 | 0.0000 ± 0.61179 | 0.2280 ± 1.21719 |
| Direct Bilirubin, Day 14 | -0.2280 ± 0.61655 | -0.4104 ± 1.21277 | -0.3705 ± 1.11040 | -0.6498 ± 0.89999 | -0.7866 ± 0.98678 | -1.0545 ± 1.05087 |
| Direct Bilirubin, Day 21 | -0.2565 ± 0.50502 | -0.4104 ± 1.12523 | -0.1140 ± 1.09047 | -0.5130 ± 0.72549 | -0.8265 ± 0.88138 | -0.9120 ± 0.97735 |
| Direct Bilirubin, Day 28 | -0.2907 ± 0.39532 | -0.6555 ± 1.80457 | -0.3990 ± 0.98331 | -0.2280 ± 0.70643 | -0.7125 ± 0.77549 | -0.5130 ± 1.16982 |
| Total Bilirubin, Baseline (Day 1) | 9.4050 ± 3.14793 | 12.8250 ± 5.59356 | 10.5450 ± 4.76555 | 11.6850 ± 2.27286 | 11.9700 ± 2.64912 | 13.6800 ± 6.11788 |
| Total Bilirubin, Day 2 | 1.3851 ± 2.24764 | -0.8835 ± 4.85401 | 3.5340 ± 4.59817 | -0.8835 ± 2.06171 | 1.6245 ± 2.72261 | 4.8450 ± 6.74934 |
| Total Bilirubin, Day 3 | 1.0260 ± 2.05042 | -0.8265 ± 5.51609 | 4.6170 ± 7.54418 | -0.3705 ± 1.79482 | 0.5415 ± 2.92088 | 3.4200 ± 7.47252 |
| Total Bilirubin, Day 4 | 0.2394 ± 2.41185 | -1.5960 ± 5.05381 | 2.1375 ± 6.66747 | -1.5390 ± 3.11577 | -1.0545 ± 2.33568 | 1.9665 ± 5.79158 |
| Total Bilirubin, Day 5 | 1.6587 ± 2.37773 | -0.3990 ± 5.95676 | 4.1040 ± 5.26169 | -1.7670 ± 2.50541 | 0.4845 ± 1.97774 | 4.0470 ± 7.46913 |
| Total Bilirubin, Day 6 | 0.7524 ± 2.27886 | -0.4560 ± 6.19451 | 3.9900 ± 6.70064 | -0.7125 ± 1.83031 | 0.2280 ± 3.36078 | 2.3655 ± 8.26581 |
| Total Bilirubin, Day 7 | 1.9323 ± 2.55682 | 0.3420 ± 6.36984 | 5.2326 ± 5.27972 | -2.1375 ± 2.49859 | 0.4845 ± 2.42655 | 4.4460 ± 6.95867 |
| Total Bilirubin, Day 14 | -0.3610 ± 1.91460 | -2.9070 ± 6.29108 | -0.5700 ± 4.06486 | -4.0698 ± 3.91698 | -3.7278 ± 3.46966 | -3.3915 ± 4.65725 |
| Total Bilirubin, Day 21 | -0.0855 ± 2.10399 | -2.5992 ± 5.51776 | 0.5130 ± 3.87835 | -3.4485 ± 2.88056 | -3.9330 ± 2.82228 | -3.1065 ± 3.89102 |
| Total Bilirubin, Day 28 | 0.1197 ± 1.42169 | -2.3655 ± 7.17501 | -1.5105 ± 4.15838 | -1.9665 ± 3.32770 | -2.7930 ± 2.63510 | -0.1995 ± 5.55096 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.
| μmol/L | Part 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB) | Part 1 (SAD): VH4011499 25 mg PiB | Part 1 (SAD): VH4011499 125 mg PiB | Part 1 (SAD): VH4011499 200 mg PiB | Part 1 (SAD): VH4011499 625 mg PiB | Part 1 (SAD): VH4011499 1875 mg PiB |
|---|---|---|---|---|---|---|
| ALP, Baseline (Day 1) | 56.4 ± 20.82 | 57.2 ± 18.96 | 53.7 ± 6.50 | 63.0 ± 5.14 | 72.0 ± 29.39 | 55.0 ± 8.07 |
| ALP, Day 2 | -4.1 ± 6.35 | -0.8 ± 3.13 | -2.5 ± 3.27 | -3.7 ± 3.50 | -4.2 ± 7.41 | -6.2 ± 2.71 |
| ALP, Day 3 | -3.3 ± 6.00 | -2.3 ± 3.39 | -3.0 ± 5.06 | -4.8 ± 4.02 | -5.7 ± 9.37 | -3.3 ± 3.39 |
| ALP, Day 4 | -1.9 ± 7.74 | -1.7 ± 3.39 | -1.2 ± 5.19 | 2.0 ± 6.39 | -2.5 ± 7.48 | -2.3 ± 2.73 |
| ALP, Day 5 | -2.5 ± 7.35 | -3.2 ± 4.07 | -1.5 ± 4.09 | -0.8 ± 5.98 | -4.0 ± 9.27 | -2.0 ± 3.46 |
| ALP, Day 6 | -2.2 ± 7.07 | -3.8 ± 3.54 | -1.3 ± 5.43 | 2.0 ± 6.42 | -4.5 ± 12.88 | -2.3 ± 3.39 |
| ALP, Day 7 | -1.8 ± 8.01 | -3.0 ± 4.20 | -3.2 ± 4.32 | 2.0 ± 6.63 | -5.3 ± 9.77 | -1.0 ± 3.16 |
| ALP, Day 14 | 0.4 ± 5.77 | 0.8 ± 8.58 | -0.5 ± 5.75 | 0.0 ± 5.15 | 0.0 ± 7.35 | -1.8 ± 3.13 |
| ALP, Day 21 | 2.1 ± 12.14 | 0.0 ± 4.90 | -0.8 ± 3.19 | 3.8 ± 8.40 | -1.8 ± 11.48 | -3.7 ± 3.44 |
| ALP, Day 28 | -0.3 ± 7.06 | 1.8 ± 3.87 | 2.0 ± 8.72 | 5.5 ± 8.48 | -3.3 ± 9.40 | -3.5 ± 3.56 |
| ALT, Baseline (Day 1) | 13.9 ± 4.38 | 28.5 ± 16.01 | 24.7 ± 9.03 | 16.0 ± 4.34 | 23.8 ± 13.11 | 21.7 ± 3.44 |
| ALT, Day 2 | 0.3 ± 1.89 | 5.5 ± 11.26 | -1.5 ± 3.39 | 0.0 ± 1.55 | -4.3 ± 3.78 | 0.2 ± 7.19 |
| ALT, Day 3 | 1.8 ± 2.44 | 5.2 ± 13.04 | -2.3 ± 3.08 | 0.5 ± 2.43 | -6.3 ± 5.20 | -1.2 ± 7.14 |
| ALT, Day 4 | 2.1 ± 3.87 | 1.5 ± 6.02 | -1.5 ± 4.28 | -0.2 ± 2.23 | -5.8 ± 5.64 | -1.3 ± 6.47 |
| ALT, Day 5 | 2.2 ± 3.49 | -1.3 ± 3.72 | -2.5 ± 3.73 | 0.2 ± 2.48 | -5.7 ± 6.35 | -2.5 ± 5.21 |
| ALT, Day 6 | 3.5 ± 4.97 | -3.8 ± 3.87 | -2.7 ± 5.54 | 1.2 ± 3.19 | -6.0 ± 7.72 | -2.5 ± 5.39 |
| ALT, Day 7 | 4.8 ± 5.96 | -5.0 ± 5.37 | -3.6 ± 5.41 | 1.3 ± 2.73 | -5.7 ± 7.45 | -1.7 ± 6.71 |
| ALT, Day 14 | 5.3 ± 5.48 | -7.0 ± 9.41 | -3.2 ± 4.45 | 0.8 ± 2.17 | -1.0 ± 6.16 | -2.0 ± 5.18 |
| ALT, Day 21 | 6.6 ± 8.78 | -2.2 ± 13.50 | 0.2 ± 8.40 | 2.2 ± 3.60 | -4.3 ± 6.89 | -3.0 ± 4.47 |
| ALT, Day 28 | 11.0 ± 17.58 | -0.3 ± 15.47 | -0.8 ± 4.12 | 0.8 ± 3.19 | -5.3 ± 8.85 | -3.5 ± 2.43 |
| AST, Baseline (Day 1) | 15.0 ± 3.53 | 20.7 ± 9.65 | 20.3 ± 3.27 | 16.2 ± 2.64 | 20.0 ± 8.07 | 21.7 ± 4.27 |
| AST, Day 2 | -0.8 ± 1.32 | 2.3 ± 9.03 | -1.2 ± 2.04 | -1.8 ± 1.83 | -5.0 ± 5.44 | -3.3 ± 4.84 |
| AST, Day 3 | 0.3 ± 2.54 | 0.3 ± 6.35 | -2.2 ± 1.94 | -2.2 ± 2.64 | -5.3 ± 6.83 | -3.8 ± 4.31 |
| AST, Day 4 | 0.1 ± 2.33 | -3.2 ± 3.76 | -1.0 ± 2.10 | -2.2 ± 2.32 | -5.2 ± 6.62 | -3.8 ± 4.02 |
| AST, Day 5 | 0.2 ± 2.44 | -5.2 ± 5.56 | -1.8 ± 0.75 | -2.0 ± 2.28 | -5.2 ± 6.88 | -4.7 ± 3.27 |
| AST, Day 6 | 0.1 ± 2.18 | -5.8 ± 6.11 | -2.0 ± 2.10 | -1.8 ± 2.64 | -5.0 ± 7.24 | -4.5 ± 3.21 |
| AST, Day 7 | 1.0 ± 3.16 | -3.7 ± 7.84 | -2.0 ± 1.58 | -1.5 ± 2.17 | -5.2 ± 7.08 | -2.5 ± 3.78 |
| AST, Day 14 | 2.7 ± 5.79 | -3.6 ± 5.03 | 0.3 ± 2.88 | 0.8 ± 0.84 | -3.0 ± 6.28 | -2.2 ± 4.96 |
| AST, Day 21 | 3.6 ± 7.57 | -2.6 ± 6.11 | 0.5 ± 4.51 | 1.3 ± 2.34 | -4.2 ± 5.78 | -2.7 ± 2.73 |
| AST, Day 28 | 5.3 ± 8.63 | 11.3 ± 17.81 | 2.5 ± 4.28 | -0.5 ± 2.43 | -4.2 ± 7.44 | -1.8 ± 3.19 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value. Standard Deviation (SD)=0.0000 is defined as following: if all participants analyzed for a specific parameter at a specific time point have the same value, then SD is equal with 0.0000.
| μmol/L | Part 2 Multiple Ascending Dose (MAD): Placebo PiB | Part 2 (MAD): VH4011499 200 mg PiB | Part 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiB | Part 2 (MAD): VH4011499 400 mg PiB |
|---|---|---|---|---|
| Direct Bilirubin, Baseline (Day 1) | 1.6856 ± 0.34805 | 1.7670 ± 0.88304 | 1.6031 ± 0.74782 | 2.5365 ± 1.12089 |
| Direct Bilirubin, Day 2 | 0.1368 ± 0.67756 | 0.1995 ± 0.43820 | — | 0.3420 ± 0.32445 |
| Direct Bilirubin, Day 3 | 0.1710 ± 0.0000 | — | 0.5130 ± 0.35400 | — |
| Direct Bilirubin, Day 5 | 0.2565 ± 1.04948 | 0.5700 ± 0.42807 | — | -0.0855 ± 0.44262 |
| Direct Bilirubin, Day 6 | 0.1710 ± 0.0000 | — | 0.8764 ± 0.54412 | — |
| Direct Bilirubin, Day 7 | 0.4703 ± 0.76950 | 0.3135 ± 0.36542 | — | 0.7125 ± 0.36542 |
| Direct Bilirubin, Day 8 | -0.0855 ± 0.12092 | — | 0.6413 ± 0.60458 | — |
| Direct Bilirubin, Day 11 | 0.5130 ± 0.91556 | 0.3990 ± 0.31838 | — | 0.5700 ± 0.46726 |
| Direct Bilirubin, Day 12 | -0.3420 ± 0.0000 | — | 0.6840 ± 0.48366 | — |
| Direct Bilirubin, Day 14 | 0.4703 ± 0.66044 | 0.3990 ± 0.36940 | — | 0.5130 ± 0.30589 |
| Direct Bilirubin, Day 15 | 0.2565 ± 0.12092 | — | 0.6413 ± 0.42628 | — |
| Direct Bilirubin, Day 21 | 0.2993 ± 0.78206 | 0.2280 ± 0.46726 | — | 0.3420 ± 0.35869 |
| Direct Bilirubin, Day 22 | 0.0855 ± 0.12092 | — | 0.4703 ± 0.53881 | — |
| Direct Bilirubin, Day 28 | -0.2052 ± 0.77800 | -0.3705 ± 0.52335 | -0.3206 ± 0.57401 | -0.6840 ± 0.71739 |
| Direct Bilirubin, Day 35 | -0.2565 ± 0.44262 | -0.3135 ± 0.61576 | -0.2779 ± 0.56298 | 0.3135 ± 0.75253 |
| Direct Bilirubin, Day 42 | -0.1710 ± 0.37464 | -0.6555 ± 0.46412 | 0.1069 ± 0.63942 | 0.0285 ± 0.89456 |
| Total Bilirubin, Baseline (Day 1) | 10.5776 ± 2.98545 | 10.0890 ± 5.90780 | 9.5760 ± 4.36923 | 12.8250 ± 6.63163 |
| Total Bilirubin, Day 2 | 2.0520 ± 4.88623 | 3.5910 ± 1.49466 | — | 4.0470 ± 1.90622 |
| Total Bilirubin, Day 3 | 0.4275 ± 0.12092 | — | 2.9284 ± 1.86301 | — |
| Total Bilirubin, Day 5 | 1.3253 ± 6.24774 | 3.6480 ± 1.09582 | — | 2.9070 ± 2.52478 |
| Total Bilirubin, Day 6 | -1.6245 ± 0.36275 | — | 3.1421 ± 2.90044 | — |
| Total Bilirubin, Day 7 | 2.1375 ± 5.96052 | 3.1350 ± 2.20495 | — | 3.6195 ± 1.75529 |
| Total Bilirubin, Day 8 | -1.7955 ± 0.12092 | — | 3.5696 ± 3.25149 | — |
| Total Bilirubin, Day 11 | 2.0520 ± 5.83575 | 3.7620 ± 2.69508 | — | 3.6195 ± 1.29517 |
| Total Bilirubin, Day 12 | -1.0260 ± 1.20915 | — | 4.2964 ± 2.74733 | — |
| Total Bilirubin, Day 14 | 1.0688 ± 4.14271 | 3.3345 ± 1.83138 | — | 2.8215 ± 1.26932 |
| Total Bilirubin, Day 15 | 0.0855 ± 1.08824 | — | 4.4033 ± 2.53263 | — |
| Total Bilirubin, Day 21 | 1.8383 ± 3.83481 | 1.8810 ± 3.11577 | — | 4.1325 ± 2.32816 |
| Total Bilirubin, Day 22 | -0.5130 ± 0.72549 | — | 2.6719 ± 3.49125 | — |
| Total Bilirubin, Day 28 | -2.5308 ± 5.31257 | -1.9665 ± 3.28525 | -2.8856 ± 2.53212 | -4.5030 ± 4.18257 |
| Total Bilirubin, Day 35 | -1.8525 ± 3.35337 | -1.8525 ± 4.50534 | -2.0306 ± 2.42251 | 2.1945 ± 4.64845 |
| Total Bilirubin, Day 42 | -1.2540 ± 2.32376 | -2.6505 ± 4.28354 | -0.9619 ± 3.56231 | 0.2280 ± 5.78644 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value. SD=0.00 is defined as following: if all participants analyzed for a specific parameter at a specific time point have the same value, then SD is equal with 0.00.
| IU/L | Part 2 Multiple Ascending Dose (MAD): Placebo PiB | Part 2 (MAD): VH4011499 200 mg PiB | Part 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiB | Part 2 (MAD): VH4011499 400 mg PiB |
|---|---|---|---|---|
| ALP, Baseline (Day 1) | 56.0 ± 16.78 | 59.5 ± 19.69 | 69.0 ± 22.43 | 53.8 ± 10.55 |
| ALP, Day 2 | -5.8 ± 12.48 | -1.2 ± 3.92 | — | -0.7 ± 3.50 |
| ALP, Day 3 | 0.0 ± 1.41 | — | -0.4 ± 2.20 | — |
| ALP, Day 5 | -6.8 ± 14.31 | 2.7 ± 5.09 | — | 0.5 ± 2.59 |
| ALP, Day 6 | 0.0 ± 1.41 | — | 0.3 ± 3.41 | — |
| ALP, Day 7 | -9.0 ± 14.31 | -0.2 ± 3.66 | — | 0.3 ± 3.33 |
| ALP, Day 8 | 0.0 ± 1.41 | — | 2.9 ± 7.32 | — |
| ALP, Day 11 | -9.0 ± 16.02 | -5.5 ± 3.89 | — | -2.7 ± 4.08 |
| ALP, Day 12 | 0.0 ± 1.41 | — | -5.0 ± 3.34 | — |
| ALP, Day 14 | -7.5 ± 15.15 | 1.5 ± 3.56 | — | -4.2 ± 3.60 |
| ALP, Day 15 | 3.5 ± 3.54 | — | -2.5 ± 3.70 | — |
| ALP, Day 21 | -9.8 ± 15.59 | -7.7 ± 6.44 | — | -3.0 ± 4.82 |
| ALP, Day 22 | 0.0 ± 1.41 | — | -5.3 ± 5.63 | — |
| ALP, Day 28 | -6.2 ± 11.23 | 0.5 ± 9.52 | -6.4 ± 4.96 | -2.5 ± 3.15 |
| ALP, Day 35 | -7.5 ± 7.79 | 3.5 ± 17.16 | -3.5 ± 6.21 | -4.8 ± 1.83 |
| ALP, Day 42 | -3.0 ± 7.48 | 0.8 ± 8.08 | -2.5 ± 3.63 | -0.3 ± 3.72 |
| ALT, Baseline (Day 1) | 23.6 ± 8.30 | 15.8 ± 4.62 | 19.5 ± 5.71 | 19.8 ± 6.24 |
| ALT, Day 2 | -2.6 ± 2.41 | 0.2 ± 1.72 | — | -0.8 ± 2.32 |
| ALT, Day 3 | -3.0 ± 1.41 | — | -2.9 ± 3.56 | — |
| ALT, Day 5 | -4.5 ± 4.20 | 0.2 ± 2.64 | — | -2.5 ± 2.74 |
| ALT, Day 6 | -7.0 ± 1.41 | — | -3.9 ± 5.82 | — |
| ALT, Day 7 | -5.5 ± 5.74 | -1.3 ± 2.07 | — | -1.0 ± 2.97 |
| ALT, Day 8 | -6.0 ± 2.83 | — | -1.4 ± 8.58 | — |
| ALT, Day 11 | -6.3 ± 6.02 | -3.3 ± 3.67 | — | -0.3 ± 5.47 |
| ALT, Day 12 | -8.5 ± 2.12 | — | -4.8 ± 7.19 | — |
| ALT, Day 14 | -4.8 ± 5.85 | -3.7 ± 4.46 | — | -1.2 ± 3.66 |
| ALT, Day 15 | -0.5 ± 6.36 | — | -1.4 ± 8.85 | — |
| ALT, Day 21 | -5.5 ± 4.65 | -3.5 ± 4.04 | — | -1.5 ± 5.47 |
| ALT, Day 22 | -7.0 ± 0.00 | — | -2.5 ± 9.43 | — |
| ALT, Day 28 | -3.4 ± 7.09 | 0.8 ± 3.66 | 1.4 ± 5.78 | 2.5 ± 8.46 |
| ALT, Day 35 | -1.2 ± 8.47 | 12.2 ± 25.97 | -1.1 ± 4.26 | -1.5 ± 4.51 |
| ALT, Day 42 | 1.0 ± 8.39 | -1.0 ± 4.29 | 1.0 ± 2.45 | 2.0 ± 4.10 |
| AST, Baseline (Day 1) | 23.3 ± 7.45 | 17.3 ± 3.44 | 18.9 ± 2.70 | 17.7 ± 3.27 |
| AST, Day 2 | -4.4 ± 5.81 | -0.8 ± 1.47 | — | -2.3 ± 2.25 |
| AST, Day 3 | -2.5 ± 0.71 | — | -1.9 ± 2.23 | — |
| AST, Day 5 | -2.5 ± 1.00 | -0.5 ± 1.87 | — | -3.7 ± 2.73 |
| AST, Day 6 | -5.5 ± 0.71 | — | -2.9 ± 3.14 | — |
| AST, Day 7 | -3.3 ± 1.89 | -1.0 ± 2.10 | — | -3.0 ± 2.45 |
| AST, Day 8 | -4.5 ± 2.12 | — | -0.9 ± 4.29 | — |
| AST, Day 11 | -5.0 ± 3.16 | -1.5 ± 1.64 | — | -4.3 ± 3.01 |
| AST, Day 12 | -5.0 ± 2.83 | — | -3.0 ± 2.45 | — |
| AST, Day 14 | -3.3 ± 2.22 | -0.7 ± 2.73 | — | -3.8 ± 2.32 |
| AST, Day 15 | -1.5 ± 2.12 | — | -1.3 ± 3.81 | — |
| AST, Day 21 | -4.0 ± 1.83 | -1.7 ± 2.25 | — | -2.7 ± 3.83 |
| AST, Day 22 | -3.5 ± 3.54 | — | -2.3 ± 3.20 | — |
| AST, Day 28 | -1.6 ± 3.13 | 0.2 ± 2.56 | 3.8 ± 9.08 | 3.0 ± 5.73 |
| AST, Day 35 | -0.8 ± 4.54 | 9.0 ± 19.07 | 1.6 ± 3.81 | 2.5 ± 5.96 |
| AST, Day 42 | 0.8 ± 5.34 | -1.0 ± 2.61 | 0.9 ± 3.44 | 3.0 ± 5.33 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.
| IU/L | Part 3 (Single Dose): VH4011499 200 mg Tablet |
|---|---|
| Direct Bilirubin, Baseline (Day 1) | 1.4250 ± 0.69810 |
| Direct Bilirubin, Day 2 | 0.7125 ± 0.89456 |
| Direct Bilirubin, Day 3 | 0.8265 ± 0.93920 |
| Direct Bilirubin, Day 4 | 0.5415 ± 0.92667 |
| Direct Bilirubin, Day 5 | 0.4104 ± 0.53531 |
| Direct Bilirubin, Day 6 | 0.8835 ± 0.98182 |
| Direct Bilirubin, Day 7 | 0.5700 ± 0.79228 |
| Direct Bilirubin, Day 14 | 0.5415 ± 0.66154 |
| Direct Bilirubin, Day 21 | 0.4275 ± 0.41536 |
| Direct Bilirubin, Day 28 | 1.2540 ± 2.25219 |
| Total Bilirubin, Baseline (Day 1) | 7.6950 ± 3.19912 |
| Total Bilirubin, Day 2 | 6.5550 ± 6.58354 |
| Total Bilirubin, Day 3 | 6.1275 ± 6.16873 |
| Total Bilirubin, Day 4 | 4.5600 ± 5.75401 |
| Total Bilirubin, Day 5 | 3.6936 ± 3.29058 |
| Total Bilirubin, Day 6 | 6.8970 ± 7.58181 |
| Total Bilirubin, Day 7 | 3.5340 ± 5.11821 |
| Total Bilirubin, Day 14 | 4.0755 ± 4.44786 |
| Total Bilirubin, Day 21 | 0.5415 ± 2.47901 |
| Total Bilirubin, Day 28 | 6.7545 ± 13.42355 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.
| IU/L | Part 3 (Single Dose): VH4011499 200 mg Tablet |
|---|---|
| ALP, Baseline (Day 1) | 52.0 ± 8.12 |
| ALP, Day 2 | -1.3 ± 6.02 |
| ALP, Day 3 | -1.0 ± 6.29 |
| ALP, Day 4 | 2.3 ± 6.31 |
| ALP, Day 5 | 5.4 ± 5.73 |
| ALP, Day 6 | 2.2 ± 6.52 |
| ALP, Day 7 | 2.7 ± 6.47 |
| ALP, Day 14 | 2.7 ± 7.17 |
| ALP, Day 21 | 0.7 ± 6.02 |
| ALP, Day 28 | 4.3 ± 5.50 |
| ALT, Baseline (Day 1) | 12.7 ± 4.03 |
| ALT, Day 2 | 2.5 ± 5.17 |
| ALT, Day 3 | 2.3 ± 5.57 |
| ALT, Day 4 | 2.3 ± 6.98 |
| ALT, Day 5 | 0.8 ± 1.64 |
| ALT, Day 6 | 2.5 ± 4.42 |
| ALT, Day 7 | 2.3 ± 3.39 |
| ALT, Day 14 | 4.8 ± 5.60 |
| ALT, Day 21 | 6.5 ± 6.66 |
| ALT, Day 28 | 2.3 ± 1.03 |
| AST, Baseline (Day 1) | 16.7 ± 1.63 |
| AST, Day 2 | 0.7 ± 3.50 |
| AST, Day 3 | -0.3 ± 2.34 |
| AST, Day 4 | -0.2 ± 2.64 |
| AST, Day 5 | -0.4 ± 1.52 |
| AST, Day 6 | 0.5 ± 1.87 |
| AST, Day 7 | -0.3 ± 1.86 |
| AST, Day 14 | 2.7 ± 3.27 |
| AST, Day 21 | 4.3 ± 7.79 |
| AST, Day 28 | 1.8 ± 2.56 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of the liver panel parameters: ALT, ALP, AST, total bilirubin and direct bilirubin. The number of participants with any grade increase (from grade 1 \[mild\] to grade 4 \[potentially life-threatening\]) have been presented.
| Participants | Part 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB) | Part 1 (SAD): VH4011499 25 mg PiB | Part 1 (SAD): VH4011499 125 mg PiB | Part 1 (SAD): VH4011499 200 mg PiB | Part 1 (SAD): VH4011499 625 mg PiB | Part 1 (SAD): VH4011499 1875 mg PiB |
|---|---|---|---|---|---|---|
| ALT, Increase to Grade 1 | 0 | 2 | 0 | 0 | 0 | 0 |
| ALT, Increase to Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT, Increase to Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALP, Increase to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALP, Increase to Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALP, Increase to Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALP, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST, Increase to Grade 1 | 0 | 2 | 0 | 0 | 0 | 0 |
| AST, Increase to Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST, Increase to Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Bilirubin, Increase to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Bilirubin, Increase to Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Bilirubin, Increase to Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Bilirubin, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Direct Bilirubin, Increase to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Direct Bilirubin, Increase to Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Direct Bilirubin, Increase to Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Direct Bilirubin, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of the liver panel parameters: ALT, ALP, AST, total bilirubin and direct bilirubin. The number of participants with any grade increase (from grade 1 \[mild\] to grade 4 \[potentially life-threatening\]) have been presented.
| Participants | Part 2 Multiple Ascending Dose (MAD): Placebo PiB | Part 2 (MAD): VH4011499 200 mg PiB | Part 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiB | Part 2 (MAD): VH4011499 400 mg PiB |
|---|---|---|---|---|
| ALT, Increase to Grade 1 | 0 | 1 | 0 | 0 |
| ALT, Increase to Grade 2 | 0 | 0 | 0 | 0 |
| ALT, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| ALT, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| ALP, Increase to Grade 1 | 0 | 0 | 0 | 0 |
| ALP, Increase to Grade 2 | 0 | 0 | 0 | 0 |
| ALP, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| ALP, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| AST, Increase to Grade 1 | 0 | 1 | 0 | 0 |
| AST, Increase to Grade 2 | 0 | 0 | 0 | 0 |
| AST, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| AST, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| Total Bilirubin, Increase to Grade 1 | 0 | 0 | 0 | 1 |
| Total Bilirubin, Increase to Grade 2 | 0 | 0 | 0 | 0 |
| Total Bilirubin, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| Total Bilirubin, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| Direct Bilirubin, Increase to Grade 1 | 0 | 0 | 0 | 0 |
| Direct Bilirubin, Increase to Grade 2 | 0 | 0 | 0 | 0 |
| Direct Bilirubin, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| Direct Bilirubin, Increase to Grade 4 | 0 | 0 | 0 | 0 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of the liver panel parameters: ALT, ALP, AST, total bilirubin and direct bilirubin. The number of participants with any grade increase (from grade 1 \[mild\] to grade 4 \[potentially life-threatening\]) have been presented.
| Participants | Part 3 (Single Dose): VH4011499 200 mg Tablet |
|---|---|
| ALT, Increase to Grade 1 | 0 |
| ALT, Increase to Grade 2 | 0 |
| ALT, Increase to Grade 3 | 0 |
| ALT, Increase to Grade 4 | 0 |
| ALP, Increase to Grade 1 | 0 |
| ALP, Increase to Grade 2 | 0 |
| ALP, Increase to Grade 3 | 0 |
| ALP, Increase to Grade 4 | 0 |
| AST, Increase to Grade 1 | 0 |
| AST, Increase to Grade 2 | 0 |
| AST, Increase to Grade 3 | 0 |
| AST, Increase to Grade 4 | 0 |
| Total Bilirubin, Increase to Grade 1 | 1 |
| Total Bilirubin, Increase to Grade 2 | 0 |
| Total Bilirubin, Increase to Grade 3 | 0 |
| Total Bilirubin, Increase to Grade 4 | 0 |
| Direct Bilirubin, Increase to Grade 1 | 0 |
| Direct Bilirubin, Increase to Grade 2 | 0 |
| Direct Bilirubin, Increase to Grade 3 | 0 |
| Direct Bilirubin, Increase to Grade 4 | 0 |
Blood samples were collected as assessed by protocol, at specific time points for pharmacokinetic (PK) analysis to determine AUC(0-inf). For AUC, a linear trapezoidal method was employed for all incremental trapezoids arising from increasing concentrations and the logarithmic trapezoidal method was used for those arising from decreasing concentrations. Geometric Coefficient of Variation was expressed in percentages.
| Hour nanogram per milliliter (h*ng/mL) | Part 1 (SAD): VH4011499 25 mg PiB | Part 1 (SAD): VH4011499 125 mg PiB | Part 1 (SAD): VH4011499 200 mg PiB | Part 1 (SAD): VH4011499 625 mg PiB | Part 1 (SAD): VH4011499 1875 mg PiB |
|---|---|---|---|---|---|
| Part 1: Area Under the Plasma Concentration Time Curve (AUC) From Time Zero to Infinity (0-inf) Following Single Dose Administration of VH4011499 | 2759.51 ± 53.69 | 8458.88 ± 20.39 | 11627.63 ± 36.01 | 24391.58 ± 34.16 | 36327.28 ± 48.29 |
Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine AUC(0-t). For AUC, a linear trapezoidal method was employed for all incremental trapezoids arising from increasing concentrations and the logarithmic trapezoidal method was used for those arising from decreasing concentrations.
| h*ng/mL | Part 2 (MAD): VH4011499 200 mg PiB | Part 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiB | Part 2 (MAD): VH4011499 400 mg PiB |
|---|---|---|---|
| Day 1/2 | 4211.67 ± 15.36 | 5385.19 ± 21.74 | 4879.14 ± 36.00 |
| Day 14/15 | 95735.06 ± 56.77 | 168459.8 ± 54.17 | 139259.6 ± 24.66 |
Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine Cmax.
| nanogram per milliliter (ng/mL) | Part 1 (SAD): VH4011499 25 mg PiB | Part 1 (SAD): VH4011499 125 mg PiB | Part 1 (SAD): VH4011499 200 mg PiB | Part 1 (SAD): VH4011499 625 mg PiB | Part 1 (SAD): VH4011499 1875 mg PiB |
|---|---|---|---|---|---|
| Part 1: Maximum Observed Plasma Concentration (Cmax) Following Single Dose Administration of VH4011499. | 26.85 ± 26.18 | 106.90 ± 17.24 | 168.88 ± 36.25 | 328.95 ± 37.97 | 557.81 ± 52.86 |
Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine Tmax.
| hours | Part 1 (SAD): VH4011499 25 mg PiB | Part 1 (SAD): VH4011499 125 mg PiB | Part 1 (SAD): VH4011499 200 mg PiB | Part 1 (SAD): VH4011499 625 mg PiB | Part 1 (SAD): VH4011499 1875 mg PiB |
|---|---|---|---|---|---|
| Part 1: Time to Maximum Observed Plasma Concentration (Tmax) Following Single Dose Administration of VH4011499 | 11.30 ± 9.51 | 10.26 ± 14.77 | 9.28 ± 11.56 | 7.86 ± 22.83 | 8.79 ± 24.60 |
Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine T1/2.
| hours | Part 1 (SAD): VH4011499 25 mg PiB | Part 1 (SAD): VH4011499 125 mg PiB | Part 1 (SAD): VH4011499 200 mg PiB | Part 1 (SAD): VH4011499 625 mg PiB | Part 1 (SAD): VH4011499 1875 mg PiB |
|---|---|---|---|---|---|
| Part 1: Apparent Terminal Half-life (T1/2) Following Single Dose Administration of VH4011499 | 63.97 ± 21.07 | 54.44 ± 23.86 | 61.61 ± 29.57 | 66.32 ± 24.75 | 55.90 ± 25.33 |
Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine Cmax.
| ng/mL | Part 2 (MAD): VH4011499 200 mg PiB | Part 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiB | Part 2 (MAD): VH4011499 400 mg PiB |
|---|---|---|---|
| Day 1 | 260.89 ± 19.62 | — | 321.37 ± 53.14 |
| Day 2 | — | 348.24 ± 20.46 | — |
| Day 14 | 1272.25 ± 42.47 | — | 1509.90 ± 22.56 |
| Day 15 | — | 1913.76 ± 22.93 | — |
Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine Tmax.
| hours | Part 2 (MAD): VH4011499 200 mg PiB | Part 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiB | Part 2 (MAD): VH4011499 400 mg PiB |
|---|---|---|---|
| Day 1 | 10.71 ± 41.53 | — | 9.50 ± 51.00 |
| Day 2 | — | 8.11 ± 22.96 | — |
| Day 14 | 4.80 ± 30.46 | — | 5.99 ± 42.79 |
| Day 15 | — | 5.27 ± 32.11 | — |
Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine T1/2.
| hours | Part 2 (MAD): VH4011499 200 mg PiB | Part 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiB | Part 2 (MAD): VH4011499 400 mg PiB |
|---|---|---|---|
| Day 14 | 51.17 ± 16.68 | — | 60.36 ± 21.81 |
| Day 15 | — | 66.47 ± 19.10 | — |
Collected over All-cause mortality, non-serious adverse events and serious adverse events were collected up to 28-days following final dose of VH4011499 or placebo (Day 28 for Part 1 and Part 3, and Day 42 for Part 2).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB) | 0/10 (0%) | 1/10 (10%) | 3/10 (30%) |
| Part 1 (SAD): VH4011499 25 mg PiB | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 1 (SAD): VH4011499 125 mg PiB | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1 (SAD): VH4011499 200 mg PiB | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part 1 (SAD): VH4011499 625 mg PiB | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1 (SAD): VH4011499 1875 mg PiB | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 2 Multiple Ascending Dose (MAD): Placebo PiB | 0/7 (0%) | 0/7 (0%) | 2/7 (28.6%) |
| Part 2 (MAD): VH4011499 200 mg PiB | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiB | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Part 2 (MAD): VH4011499 400 mg PiB | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 3 (Single Dose): VH4011499 200 mg Tablet | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Event | Part 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB) | Part 1 (SAD): VH4011499 25 mg PiB | Part 1 (SAD): VH4011499 125 mg PiB | Part 1 (SAD): VH4011499 200 mg PiB | Part 1 (SAD): VH4011499 625 mg PiB | Part 1 (SAD): VH4011499 1875 mg PiB | Part 2 Multiple Ascending Dose (MAD): Placebo PiB | Part 2 (MAD): VH4011499 200 mg PiB | Part 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiB | Part 2 (MAD): VH4011499 400 mg PiB | Part 3 (Single Dose): VH4011499 200 mg Tablet |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-cardiac chest painGeneral disorders | 1/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/7 | 0/6 | 0/8 | 0/6 | 0/6 |
| Event | Part 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB) | Part 1 (SAD): VH4011499 25 mg PiB | Part 1 (SAD): VH4011499 125 mg PiB | Part 1 (SAD): VH4011499 200 mg PiB | Part 1 (SAD): VH4011499 625 mg PiB | Part 1 (SAD): VH4011499 1875 mg PiB | Part 2 Multiple Ascending Dose (MAD): Placebo PiB | Part 2 (MAD): VH4011499 200 mg PiB | Part 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiB | Part 2 (MAD): VH4011499 400 mg PiB | Part 3 (Single Dose): VH4011499 200 mg Tablet |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/7 | 2/6 | 0/8 | 0/6 | 0/6 |
| NauseaGastrointestinal disorders | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/7 | 2/6 | 0/8 | 0/6 | 0/6 |
| VomitingGastrointestinal disorders | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/7 | 2/6 | 0/8 | 0/6 | 0/6 |
| Activated partial thromboplastin time prolongedInvestigations | 0/10 | 0/6 | 0/6 | 2/6 | 0/6 | 0/6 | 0/7 | 0/6 | 0/8 | 0/6 | 0/6 |
| HeadacheNervous system disorders | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/7 | 2/6 | 1/8 | 0/6 | 0/6 |
| SomnolenceNervous system disorders | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/7 | 0/6 | 2/8 | 0/6 | 0/6 |
| Blood creatine phosphokinase increasedInvestigations | 2/10 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/7 | 0/6 | 0/8 | 0/6 | 0/6 |
| Infrequent bowel movementsGastrointestinal disorders | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/7 | 1/6 | 0/8 | 0/6 | 0/6 |
| Influenza like illnessGeneral disorders | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/7 | 1/6 | 0/8 | 0/6 | 0/6 |
| Medical device site dermatitisGeneral disorders | 0/10 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/7 | 0/6 | 0/8 | 0/6 | 1/6 |
Baseline characteristics presented based on Exposed population.
| Age, Continuous(Years) | Part 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB) | Part 1 (SAD): VH4011499 25 mg PiB | Part 1 (SAD): VH4011499 125 mg PiB | Part 1 (SAD): VH4011499 200 mg PiB | Part 1 (SAD): VH4011499 625 mg PiB | Part 1 (SAD): VH4011499 1875 mg PiB | Part 2 Multiple Ascending Dose (MAD): Placebo PiB | Part 2 (MAD): VH4011499 200 mg PiB | Part 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiB | Part 2 (MAD): VH4011499 400 mg PiB | Part 3 (Single Dose): VH4011499 200 mg Tablet | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 37.8 ± 11.17 | 35.3 ± 6.12 | 36.5 ± 7.48 | 45.8 ± 8.08 | 40.0 ± 12.05 | 39.8 ± 7.78 | 37.6 ± 11.18 | 35.5 ± 13.10 | 38.9 ± 11.81 | 32.3 ± 3.83 | 37.2 ± 9.91 | 37.9 ± 9.72 |
| Sex/Gender, Customized(Participants) | Part 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB) | Part 1 (SAD): VH4011499 25 mg PiB | Part 1 (SAD): VH4011499 125 mg PiB | Part 1 (SAD): VH4011499 200 mg PiB | Part 1 (SAD): VH4011499 625 mg PiB | Part 1 (SAD): VH4011499 1875 mg PiB | Part 2 Multiple Ascending Dose (MAD): Placebo PiB | Part 2 (MAD): VH4011499 200 mg PiB | Part 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiB | Part 2 (MAD): VH4011499 400 mg PiB | Part 3 (Single Dose): VH4011499 200 mg Tablet | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | 9 | 6 | 6 | 5 | 5 | 6 | 7 | 5 | 7 | 6 | 6 | 68 |
| Female | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 5 |
| Race/Ethnicity, Customized(Participants) | Part 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB) | Part 1 (SAD): VH4011499 25 mg PiB | Part 1 (SAD): VH4011499 125 mg PiB | Part 1 (SAD): VH4011499 200 mg PiB | Part 1 (SAD): VH4011499 625 mg PiB | Part 1 (SAD): VH4011499 1875 mg PiB | Part 2 Multiple Ascending Dose (MAD): Placebo PiB | Part 2 (MAD): VH4011499 200 mg PiB | Part 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiB | Part 2 (MAD): VH4011499 400 mg PiB | Part 3 (Single Dose): VH4011499 200 mg Tablet | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asian | 2 | 0 | 0 | 2 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 7 |
| Black or African American | 3 | 3 | 3 | 1 | 2 | 1 | 3 | 3 | 5 | 4 | 1 | 29 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| White | 5 | 2 | 2 | 2 | 4 | 1 | 3 | 3 | 3 | 2 | 3 | 30 |
| Multiple | 0 | 1 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Study sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.viiv-studyregister.com
Ran from Oct 2022 to primary completion in Apr 2023, 6 months.
Results were first posted in Apr 2025, 1 year 11 months after primary completion.
Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 6 months is above that.
Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dezecapavir